Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Declines By 26.3%

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a significant decline in short interest in November. As of November 15th, there was short interest totalling 600,000 shares, a decline of 26.3% from the October 31st total of 813,800 shares. Based on an average daily volume of 524,300 shares, the days-to-cover ratio is currently 1.1 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP boosted its holdings in shares of Vincerx Pharma by 359.1% in the 2nd quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after acquiring an additional 256,967 shares in the last quarter. Armistice Capital LLC acquired a new position in shares of Vincerx Pharma in the 2nd quarter worth approximately $1,610,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Vincerx Pharma by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock worth $3,375,000 after acquiring an additional 153,575 shares in the last quarter. 44.02% of the stock is owned by institutional investors and hedge funds.

Vincerx Pharma Stock Performance

NASDAQ VINC traded up $0.02 during trading on Friday, reaching $0.29. 127,122 shares of the company traded hands, compared to its average volume of 668,223. The company has a market cap of $9.56 million, a price-to-earnings ratio of -0.28 and a beta of 1.60. Vincerx Pharma has a 1-year low of $0.24 and a 1-year high of $9.37. The stock’s 50 day moving average price is $0.43 and its two-hundred day moving average price is $0.60.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners decreased their price objective on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.